Stock 0C1 ATRECA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Atreca, Inc.

Equities

0C1

US04965G1094

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 03:58:21 2024-03-28 pm EDT 		5-day change 1st Jan Change
0.0435 EUR -62.17% Intraday chart for Atreca, Inc. -.--% -62.17%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 369.1 462.5 101 30.67 1.725 1.725 -
Enterprise Value (EV) 1 369.1 462.5 101 30.67 1.725 1.725 1.725
P/E ratio - - - - - - -
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - -5,346,750 x -955,525 x - - - -
EV / FCF -5,954,381 x - -1,052,491 x -375,804 x - - -
FCF Yield -0% - -0% -0% - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 27,961 36,707 37,151 39,067 39,653 39,653 -
Reference price 2 13.20 12.60 2.720 0.7850 0.0435 0.0435 0.0435
Announcement Date 3/11/20 2/25/21 3/3/22 3/29/23 - - -
1EUR in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales - - - - - - - -
EBITDA - - -86.5 -105.8 - - - -
EBIT - -72.57 -88.88 -110.3 -98.3 - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - -67.48 -86.33 -109.3 -97.16 - - -
Net income -37.94 -67.48 -86.34 -109.3 -97.16 - - -
Net margin - - - - - - - -
EPS - - - - - - - -
Free Cash Flow - -61.98 - -96.01 -81.61 - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 4/24/19 3/11/20 2/25/21 3/3/22 3/29/23 - - -
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - -62 - -96 -81.6 - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - 3.45 5.03 35.1 0.89 - - -
Capex / Sales - - - - - - - -
Announcement Date 4/24/19 3/11/20 2/25/21 3/3/22 3/29/23 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ATRECA, INC. Stock Atreca, Inc.
-62.17% 1.84M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
ARGENX SE Stock argenx SE
+17.23% 25.91B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.47% 15.56B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 0C1 Stock
  4. Financials Atreca, Inc.